Pfizer, Moderna Seek New Revenue Streams as COVID Vaccine Demand Declines
-
Pfizer and Moderna shares have plunged due to declining COVID-19 vaccine demand, but could rebound as they launch new products.
-
Pfizer is launching 19 new products and making acquisitions like Seagen to drive future growth.
-
Moderna's RSV vaccine could enable organic sales growth by 2025 if approved, with other pipelines like flu and CMV.
-
Wall Street price targets show upside potential for both stocks, but Pfizer offers dividends and value.
-
Both stocks could bounce back in a bull market, but have faced challenges replacing COVID-19 revenue streams.